

FIGHTING OPIOID DEPENDENCE FROM A STRONG PLATFORM

Orexo is a fully integrated specialty pharmaceutical company, with a strong track record of developing products approved worldwide.

SALSS CONTACT

Nikolaj Sørensen
CEO

nikolaj.sorensen@orexo.com
Switchboard +46 (0)18 780 88 00

Orexo AB
Box 303
SE-751 05 Uppsala
Sweden

Visiting address Rapskatan 7E

SALSS PRESENTING COMPANY | 2018

orexo

OREXO AB | STO:ORX | OTCQX:ORXOY(ADR)

Orexo AB is a listed specialty pharmaceutical company which develops improved pharmaceuticals based on innovative drug delivery technologies. Orexo has three products on market, of which one - Zubsolv® for treatment of opioid dependence - is commercialized in-house by Orexo in the US. The development pipeline contains projects in different phases, with a primary therapeutic focus around addiction in all phases.

OUR PRODUCTS & SERVICES

The key product Zubsolv® helps patients suffering from opioid dependence, which is an escalating epidemic and the most common cause of death from drug overdose today. The US saw over 60,000 deaths from overdose in 2016, mainly caused by opioid use.

Orexo has developed four products from idea to patient, all utilizing proprietary sublingual formulation technology and commercialized through Orexo or selected partners.

- Zubsolv® is on market in the US and the EU, for opioid dependence and partnered with Mundipharma outside the US.
- Abstral® for breakthrough cancer pain, is partnered with Kyowa Kirin and Sentyln Therapeutics worldwide.
- Edluar® for sleeping problems, is partnered with Mylan worldwide.
- Diabact® for diagnosing stomach ulcer bacteria, is now owned by Kibion, a subsidiary that Orexo sold in 2015, and commercialized worldwide.

WHAT MAKES US UNIQUE

Orexo is working to address the most severe health issue currently in the US, with it's own commercial business unit in the US and R&D in Uppsala, Sweden. Experience from taking four products from idea to patient has created a strong understanding of all development phases and the requirements for product approval. Based on its presence in the US, where Orexo commercializes Zubsolv® for treatment of opioid dependence, the company has in-depth understanding of patient needs in the fast growing therapeutic area of addiction. Orexo also has a strong financial base to invest in new development projects and broaden the US commercial platform.

WHY YOU SHOULD MEET US

As an important objective is to expand the US commercial platform, Orexo is continuously searching for commercial stage opportunities to address the needs of patients suffering from addiction. Orexo is also working intensively to expand the pipeline of clinical stage projects within the therapeutic area of addiction and to increase the breath of technologies available for new products. This process will be performed internally or together with partners, e.g. by in-licensing.

KEY TEAM

Nikolaj Sørensen

• President & CEO

Robert DeLuca

• President Orexo US, Inc.

Henrik Juuel

• EVP & Chief Financial Officer

Johannes Doll

• EVP & Head of Corporate Development

Michael Sumner

• Chief Medical Officer

Jesper Lind

• Chief Operations Officer

SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2018